The latest report by IMARC Group, titled “Opioids Market Report by Product Type (Codeine, Fentanyl, Methadone, Oxycodone, Morphine, Hydrocodone), Application (Pain Management, Cough Treatment, Diarrhea Treatment, and Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Drug Stores, Online Stores, and Others), and Region 2025-2033,” finds that the global opioids market size reached USD 22.5 Billion in 2024. Opioids refer to naturally occurring, synthetic, or semi-synthetic drugs that interact with opioid receptors in the nervous system and activate them. These potent medicines include morphine, codeine, oxycodone, hydrocodone, and methadone. They decrease the pain of treatments and injuries by preventing the pain signals from reaching other parts of the body. Opioids can be administered through intravenous (IV) injection or taken through oral and transdermal routes. They are prescribed by healthcare professionals as they are safe, cost-effective and easily available. As a result, they are majorly used to treat the pain associated with rheumatic diseases, cancer, anxiety, sleep disorder, and severe pain related to coughing and diarrhea.
Global Opioids Market Trends:
The market is primarily driven by the increasing prevalence of chronic pain associated with diseases such as cancer, arthritis, lower back pain, fibromyalgia, and post-surgical pain. Opioids are standard practice in most parts of the world as an effective way of managing chronic pain. In addition to this, the rising consumption of alcohol and tobacco, coupled with the occurrences of obesity, human papillomavirus (HPV) and multiple sunburns are also propelling the market growth. Furthermore, the growing number of individuals undergoing surgery has positively influenced the demand for opioids, especially in controlling post-surgical pain, speedy recovery, and reducing the chances of complications in patients. Moreover, the rising focus on the abuse-deterrent formulation (ADF) by generic manufacturers has resulted in the introduction of new opioid variants, which, in turn, is escalating their demand as effective drugs for pain management. Looking forward, the market value is projected to reach USD 28.8 Billion by 2033, expanding at a CAGR of 2.65% during 2025-2033.
Market Summary:
Report Features | Details |
---|---|
Base Year of the Analysis | 2024 |
Historical Period | 2019-2024 |
Forecast Period | 2025-2033 |
Units | Billion USD |
Segment Coverage | Product Type, Application, Distribution Channel, Region |
Region Covered | Asia Pacific, Europe, North America, Latin America, Middle East and Africa |
Countries Covered | United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico |
Companies Covered | Boehringer Ingelheim International GmbH, Hikma Pharmaceuticals PLC, Mallinckrodt plc, Pfizer Inc., Purdue Pharma L.P., Sanofi S.A., Sun Pharmaceutical Industries Ltd. and Teva Pharmaceutical Industries Ltd. |
Customization Scope | 10% Free Customization |
Post-Sale Analyst Support | 10-12 Weeks |
Delivery Format | PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |
About Us:
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
Contact Us:
IMARC Group
30 N Gould St, Ste R
Sheridan, WY (Wyoming) 82801 USA
Email: Sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
Americas:- +1 631 791 1145 | Africa and Europe :- +44-753-713-2163 | Asia: +91-120-433-0800